TrialChinese medical journal2021

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.

Xiaonan Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.